TP-271
- Generic Name
- TP-271
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H31FN4O8
- CAS Number
- 1207284-17-0
- Unique Ingredient Identifier
- Y6IUM7395Q
- Background
TP-271 is under investigation in clinical trial NCT02724085 (A Phase 1 Study to Assess the Safety, Tolerability and PK of IV TP-271).
- Associated Conditions
- -
- Associated Therapies
- -
A Phase 1 TP-271 Oral PK Multiple Ascending Dose Study
- First Posted Date
- 2018-03-01
- Last Posted Date
- 2021-12-17
- Lead Sponsor
- Tetraphase Pharmaceuticals, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT03450187
- Locations
- 🇺🇸
PPD Phase I Clinic, Austin, Texas, United States
A Phase 1 Safety and PK Study of IV TP-271
- First Posted Date
- 2017-07-31
- Last Posted Date
- 2021-12-13
- Lead Sponsor
- Tetraphase Pharmaceuticals, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT03234738
- Locations
- 🇺🇸
PPD Phase 1 Clinic, Austin, Texas, United States
A Phase 1 TP-271 Oral PK Single Ascending Dose Study
- First Posted Date
- 2017-01-18
- Last Posted Date
- 2021-12-13
- Lead Sponsor
- Tetraphase Pharmaceuticals, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT03024034
- Locations
- 🇺🇸
PPD Phase 1 Clinic, Austin, Texas, United States
A Phase 1 Study to Assess the Safety, Tolerability and PK of IV TP-271
- First Posted Date
- 2016-03-31
- Last Posted Date
- 2021-12-13
- Lead Sponsor
- Tetraphase Pharmaceuticals, Inc.
- Target Recruit Count
- 57
- Registration Number
- NCT02724085
- Locations
- 🇺🇸
PPD Phase 1 Clinic, Austin, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath